Jaing, Tang-Her, and Yi-Lun Wang. 2020. “Epstein-Barr Virus Reactivation and Post-Transplant Lymphoproliferative Disease Risk Deserve a Place in the JAK Inhibitor Toxicity Profile. Comment On: ‘Janus Kinase Inhibitors As an Evolving Treatment for Lymphomas and Immune-Mediated complications’”. Haematologica, September. Pavia, Italy. https://doi.org/10.3324/haematol.2026.301889.